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Abstract
The purpose of this thesis is to examine familial hypercholesterolemia (FH) and emerging
pharmacogenomics therapies that propose to lower serum low density lipid (LDL) levels. The
search of various data bases resulted in nine research articles being selected for review.
Syntheses of the articles suggest emerging phamacogenomic drug therapy can improve treatment
outcomes for individuals with a diagnosis of FH. The Human Genome Project (HGP) has had far
reaching applications for genomic technologies and pharmacagenomic interventions, tailored to
human conditions associated with select genomic traits. Synthesis of nine research articles
demonstrate that little is known on the topic and reveals extensive gaps in the evidence. This
thesis concludes with implications for nursing education, practice, policy and research along with
limitations are noted.
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Introduction
The Human Genome Project (HGP), completed in 2003, involved an international cadre
of researchers who mapped the sequence of all human genes to develop the genome of the
species Homo sapiens. Metaphorically, sequencing of the human genome provides a textbook
with pages for each gene describing the makeup of the human body. This knowledge has led to
the discovery of more than 1,800 disease genes such as Familial hypercholesteremic (FH)
(National Institute of Health, 2015). An outcome of the HGP has assisted researchers in
identifying a particular gene suspected of causing a specific inherited disease in a matter of days,
rather than years. Since the HGP was completed more than 2,000 genetic tests have been
developed to identify various human conditions. Another outcome of the HGP resulted in
improved genetic testing which allows for specific identification of gene mutations within a
strand of deoxyribonucleic acid (DNA) that could determine if a person or family is at genetic
risk for developing a particular condition. Likewise, DNA screening can assist the healthcare
provider in diagnosing diseases with greater accuracy and then personalizes medical and
pharmacological intervention to treat the genetically based condition (National Institute of
Health, 2015).
Excessive serum cholesterol (hypercholesterolemia) in the body greatly increases an
individual’s risk of developing cardiac and other vascular related diseases. Familial
hypercholesterolemia (FH), a rare genetic condition, is associated with an excessive and
persistent accumulation of cholesterol in the blood. It is estimated that one in every 500
individuals has the genetic propensity for developing FH evidenced by high serum cholesterol
levels (National Human Genome Research Institute, 2015). There are two types of cholesterol
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that people are most familiar with, high density lipoprotein (HDL) and low density lipoprotein
(LDL). Sometimes referred to as "good cholesterol” the HDL ‘picks up’ excess cholesterol in the
blood and disperses it to the liver where it is then broken down. A high level of LDL or ‘bad
cholesterol’ over time accumulates in blood vessel wall linings (plaques) throughout the body
which results in narrowing of vessel. Eventually, plaques can block blood flow which increases
the risk of developing coronary artery disease, vascular disease and stroke.
Serum cholesterol level is measured in milligrams (mg) of cholesterol per deciliter (dL)
of blood or mill moles (mmol) per liter (L). Regarding the targeted serum level of HDL, the goal
should be having a higher number, while for LDL the goal should be for a lower number. One
diagnostic measure for FH is having a persistent serum LDL level above >190mg/dL (National
Library of Medicine, 2015). A treatment goal for individuals with FH is to maintain a serum
LDL level of <190mg/dL (High cholesterol, 2015; Learning about familial hypercholesterolemia,
2015) (See Table 1.). The HGP along with facilitating quicker diagnoses, led to development of
new classifications of drugs to treat genetically based FH (pharmacogenomics) that tailor
treatment approaches for an individual (precision medicine). Ultimately, precision medicine can
improve treatment outcomes and reduce long term comorbidities, in this case FH which is the
focus of this thesis.

Problem Statement
The purpose of this integrative review was to examine the effects of pharmacogenomics
in managing or reducing serum cholesterol levels in individuals who have been diagnosed with
FH.
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Rational/Purpose
Recently genomics, pharmacogenomics and precision medicine received extensive media
attention at the national level. In his 2016 State of the Union Address, President Obama launched
a $215 million Precision Medicine Initiative in the 2016 Federal Budget. His initiative focuses
on research and data-sharing among researchers and clinicians to advance an agenda of precision
medicine and its effects on treatment and outcomes (Williams et al., 2016). In respect to nursing
education, the American Nurses Association along with other specialty nursing organizations
recommend that curricula include content on genetics to enhance genomic nursing competencies
in graduates (Cheek, Bashore, & Brazeau, 2015; Greco, Tinley, & Seibert, 2011; Howington,
Riddlesperger, Cheek, 2011). Given these two nationally focused imperatives, this integrative
review will focus on pharmacogenomic therapy outcomes in individuals with a diagnosis of FH.
Table 1. Diagnostic Parameters for Serum Cholesterol Levels.

HDL

LDL

Familial Hypercholesterolemia

Normal: 60 mg/dL or
above

Normal: 130 mg/dL or
below

LDL: > 190 mg/dL or more

At Risk: 40 mg/dL or
below

HDL: < 60 mg/dL
At Risk: More than
130mg/dL

Note. Adapted from “High Cholesterol,” by Mayo Clinic, 2016, http://www.mayoclinic.org/diseasesconditions/high-blood-cholesterol/in-depth/hdl-cholesterol/ART-20046388

Background
Treatment of choice for managing hypercholesterolemia historically comprised lifestyle
behavior modifications and administration of HMG-CoA reductase inhibitors (i.e., statins).
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However, in individuals diagnosed with FH, lifestyle changes coupled with statin drug therapy
generally is ineffective in lowering serum cholesterol, in particular LDL, to recommend target
levels (Kolovou, Vasiliadis, Gontoras, Kolovou, & Hatzigeorgiou, 2015). Satin drugs can have a
high degree of variability in lowering LDL especially in individuals with FH associated with
genetic factors that impact drug responsiveness. For individuals who are resistant to traditional
interventions to manage hypercholesterolemia, genetic screening could be the next step in the
treatment care plan.
Genetic Screening
Genetic screening may be recommended for individuals who persistently maintain a high
serum LDL even with lifestyle modifications (dietary; physical activity) along with statin
medication regimen (Thomas, 2014). An individual can have the genetic traits for heterozygous,
homozygous or polygenic FH. All three of these genetic mutations are associated with an
increased serum LDL that is deposited throughout the body which pose risks for developing
coronary heart and other vascular diseases. Other physical manifestations of FH include
xanthomas in the eyes, tendons, elbows, hands and knees. Average life expectancy in the US of
persons with FH is estimated to be in the early twenties if left untreated compared with a life
expectancy of 78.7 years of an individual who does not have the condition (Thomas, 2014).
Individuals having the heterozygous (HeFH) genetic trait have either one mutation in a
single gene or multiple mutations in different genes. They are at significant risk for a premature
heart attack which is 20 times higher than the general population. Coronary complications are
more likely to occur in males with this genetic trait (50%) before 50 years of age and in females
(30%) before 60 years of age (Sniderman, Tsimik & Fazio, 2014).
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Individuals with the homozygous (HoFH) genetic trait have two mutated copies of the
same gene that causes a specific type of FH. Individuals with this genetic trait are at even
greater risk of developing CHD and other elevated serum LDL level associated complications.
For example, with HoFH acute coronary attacks and cardiac disease can occur in an individual
even before the end of the second decade of life (Sniderman, Tsimikas & Fazio, 2014).
The polygenic genetic phenotype of FH, involves a combination of any of 12 different
single nucleotide polymorphisms in select genes that are believed to be associated with FH.
Precise epidemiological and bio statistical information on this genotype was not available in the
literature (Sniderman, Tsimikas & Fazio, 2014).
Genomics and Emerging Pharmacogenomic Interventions
The HGP identified three specific genetic traits that lead to developing FH, specifically
the Low Density Lipoprotein Receptor Gene (LDLR), the Proprotein Convertase Substilin/Kexin
9 gene (PCSK9), and the Apolipoprotein B (APOB) gene. Each of these genetic traits will be
discussed in the next few paragraphs (Sniderman, Tsimikas & Fazio, 2014).
The LDLR gene, most commonly associated with FH, is responsible for construction of
LDL receptors throughout the body and thereby removing LDL from the blood. This particular
gene is integral to controlling serum LDL levels. In turn, an insufficient amount of LDL
receptors impairs LDL absorption resulting in high level of LDL circulating in the blood
resulting in hypocholesteremia (Sniderman, Tsimikas & Fazio, 2014). .
The PCSK9 gene controls the circulating amount of the PCSK9 protein which regulates
the number of LDL receptors that adhere to the surfaces of cells. Mutations in the PCSK9 gene
can lead to either an increase or decrease in activity of the protein regulators. An increase in
activity will lead to an increase in the breakdown of LDL receptors throughout the body; thus,
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circulating LDL is not being absorbed by LDL receptors, resulting in hypercholesterolemia.
Decreasing the activity of the PCSK9 protein can result in less destruction of LDL receptors;
thereby lowering the circulating level of LDL (Sniderman, Tsimikas & Fazio, 2014).
The APOB gene encodes for the APOB protein which transports cholesterol throughout
the body and allows the lipoprotein to attach to LDL receptors for absorption. When the gene
mutates the APOB protein does not form correctly and impedes the LDL receptor from binding
and absorbing LDL, resulting in hypocholesteremia (Sniderman, Tsimikas & Fazio, 2014).
Therapeutic Management of FH
First line treatment for FH includes the management of cholesterol through lifestyle
modification such as limiting animal fat intake to less than 30% of total calories. This can be
accomplished by reducing or eliminating animal fats such as pork, beef and dairy products.
Another lifestyle modification focuses on increasing physical activity which in some cases also
lowers serum LDL cholesterol. If lifestyle modification are not effective pharmacological
therapies may be started, the most common being statin drugs. Statins generally are effective for
lowering serum LDL levels in most individuals; however, those with FH often demonstrate
lower or no less therapeutic response to statins (National Human Genome Research Institute,
2015). Recent genetically based FH pharmacologic interventions can personalize treatment
options to manage hypercholesterolemia based on genetic traits such as PCSK9 inhibitors,
APOB inhibitors and MTP inhibitors (Sniderman, Tsimikas & Fazio, 2014) (See Table 2).
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Table 2. Genetic Trait, Pharmacogenetics Therapies and Actions.
Gene Trait

Pharmacogenetics Therapies

Action

Proprotein Convertase

alirocumab (Praluent),

Monoclonal antibodies

Substilin/Kexin 9

evolocumab (Repatha)

that destroys the PCSK9
protein.

Apoliprotien B

mipomersen sodium(Kynamro)

Inhibits synthesis of
APOB protein in the liver

Microsomal Triglyceride

lomitapide (Juxtapid)

Transfer Protein

Inhibits MTP which is
essential in the formation
of very low density lipids

Note. Adapted from “The Severe Hypercholesterolemia Phenotype.” by Sniderman, A. D., Tsimikas, S., & Fazio, S,
2014, Journal of the American College of Cardiology, 63(19), 1935-1947.

Methods
This thesis presents an integrative review of literature that focused on pharmacologic and
lifestyle management of hyperlipidemia in FH. Key terms used in the literature search included:
“pharmacogenomics,” “pharmacogenetics,” “genetics,” “familial hypercholesterolemia,”
“dyslipidemia,” “genetic screening,” “PCSK9,” “APOB,” “MTP inhibitors,” “statins.” Databases
for the search included CINAHL, Medline, PubMed and Cochrane. Inclusion criteria were peerreviewed research articles published from 2009 to 2015, and written in the English language.
Each article was individually evaluated for relevance to the topic and application to FH therapy.
A table that summarizes findings from each was developed and is included in the appendices
7

(see appendix B). Subsequently all of the critiques were synthesized by the researcher and key
data were extracted. Consistent and inconsistent findings were noted along with gaps in the
literature. Recommendations for future research were identified. Implications for nursing
practice, policy and education are included along with limitations of this review.
Eight studies were included in the final analysis and an additional nine articles gave
further relevance to this review. Primary searches contained the search terms
“pharmacogenomics” or “pharmacogenetics” which yielded N=18,312 studies. Once the topic of
FH was chosen subsequent searches contained the search term “familial hypercholesterolemia”
and included a specific type of pharmacogenomic therapy (“PCSK9,” “APOB,” “MTP” and
“inhibitor”) associated with FH. Each search included the drug class and FH, and an additional
limiting factor was the inclusion of statins as a comparison drug, and eight studies met inclusion
criteria (see appendix A). Seven of the studies where randomized, double-blind, placebocontrolled experiments; one was a case-study; seven studies used humans as study subjects; and,
one used mice. Of these, three studies examined the use of Evolocumab, a PCSK9 inhibitor as
potential genetically targeted drug therapy for individuals with FH; another two studies
examined Mipomersen an Apoliprotein B protein inhibitor; and, three other studies examined
Lomitapide an MTP inhibitor. In addition to the eight studies, searches that yielded articles that
did not include original findings but were useful in giving background information were included
(n=9) along with other pertinent and relevant sources such as webpages (n=4).

Results
This next section highlights each pharamacogenomic therapy in depth using data from
drug trials, case-studies and experiments. Results and limitations are noted in each subheading.
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Following this is a discussion of the results and the implications of these therapies on individuals
with FH.
PCSK9 Inhibitors
The literature indicated that PCSK9 is not involved in the synthesis of cholesterol. For
this reason statins tend to be ineffective in individuals with PCSK9 induced FH thus creating the
need for another type of intervention. Statins are correlated with a direct increase in PCSK9
levels in individuals with PCSK9 induced FH. Consequently, statin drugs not only are ineffective
but not beneficial in reducing the etiological agent of this classification of FH (Faiz, Hooper, &
Bockxmeer, 2012).
In a study of the PCSK9 inhibitor alirocumab, (i.e. ODYSSEY COMBO I Study)
(N=316) patients at high cardiovascular risk were administered a PCSK9 inhibitor with a statin
medication of which they were at the maximally tolerated dose. In a multicenter study located in
76 sites across the US, data were collected for a phase 3, randomized, double-blind 52 week trial
study to observe the effectiveness of alirocumab. Participating subjects over 18 years of age,
with an established diagnoses of coronary heart disease, persistent hypercholesterolemia having
either as serum LDL>70 with coronary artery disease (CAD); or, serum LDL>100 and CAD
risk equivalents (e.g. diabetes, hypertension, kidney disease, obesity). The study findings
indicated that the PCSK9/Statin combo lowered LDL 48% from baseline compared to the serum
LDL level in subjects receiving only a statin drug. After 24 weeks of administration of a PCSK9
75mg every 2 weeks lead to a mean LDL of 51 mg/dl vs statin alone (98 mg/dl) in patients with
hypercholesterolemia despite maximally tolerated statin therapy (Kereiakes et al., 2015).
Combination of alirocumab in adjunct to a statin reduced LDL from baseline by 48.2% where as
placebo and statin therapy reduced LDL by 2.3% by week 24. This equated to a mean difference

9

of 45.9% in baseline LDL (P<.0001) between the alirocumab group and the placebo group.
Weaknesses of the study include no evidence of subgroup analyses for race or gender. This study
did not target the effectiveness of the drug on individuals with FH, yet the findings are still
pertinent since individuals with FH often have been on maximally tolerated statin therapy.
In a double blind study by Raal, et al., (2015) PCSK9 inhibitors focused on subjects
(N=49) with HoFH. Of these, n=16 participants were administered a placebo and n=33 received
the drug evolocumab, a PCSK9 inhibitor. All subjects were positive for HoFH and had been on
lipid lowering therapy for at least 4 weeks (Raal et al., 2015). After 12 weeks of evolocumab
administration a 30.9% reduction in serum LDL and 23% reduction in Apob resulted compared
to the placebo group (P<0.0001) (Raal et al., 2015).
Lastly, in another study (N= 331) heterozygous subjects received PCSK9 therapy
administered evolocumab either on a monthly basis (420 mg) or every 2 weeks (140 mg). Both
groups had statistically significant reduction in serum LDL levels. Subjects receiving the
monthly dose by the end of 12 weeks had a 61.3% reduction in serum LDL levels compared to
the placebo group. This finding equates to a treatment difference of 59.2% (P<0.0001). Biweekly doses of 140 mg led to a reduction in serum LDL of 59.2% compared to a placebo
(P<0.0001) (Raal et al., 2015).
Limitations of the research include the analysis of responses to therapy based on
genotype was completed post-hoc rather than being pre-specified in the study methods or data
collection plans. Thus, this approach was used to determine the hypotheses and should not be
viewed as findings. Also the study time frame was only 12 weeks, and for that reason durability
of serum LDL reductions and safety could not be ascertained.
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It is clear that the administration of PCSK9 inhibitors in both patients with or without FH
can have significant serum LDL lowering results. In conditions that are of genetic nature, statins
alone can be ineffective in lowering LDL concentrations and PCSK9 inhibitors can enhance
statins in lipid lowering. This is especially important since statins alone can raise PCSK9 levels
in individuals, subsequently FH, this approach exacerbatesin individuals with a PCSK9 gene
mutation where PCSK9 proteins are already numerous in serum concentration. Also, in patients
who do not tolerate statins, this therapy could aid in lowering LDL while titrating the statin dose
downward. This strategy could relieve patients of statin induced side effects from poor tolerance
to the drug or high doses.
APOB Inhibitors (mipomersen)
Mipomersen is an antisense agent that inhibits APOB synthesis and reduces the amount
of APOB containing lipoproteins in circulation. When used in individuals with mild
hypercholesterolemia or even homozygous FH this drug significantly reduced the concentration
of circulating LDL and APOB. When combined with other lipid-lowering therapies it is even
more effective (Stein et al., 2012). In a double-blind, placebo-controlled trial (N=114) subjects
were administered mipomersen weekly at 200 mg resulted in a 28% decrease in LDL levels in
HeFH individuals with CAD who could not achieve LDL control of <100mg/dl on maximum
lipid-lowering therapy. Mipomersen is unique as it reduces LDL concentration at almost the
same rate for both HeFH and HoFH individuals. Mipomersen lowered LDL by 25% in HoFH
subjects and 28% in HeFH subects (Stein et al., 2012). The LDL lowering ability of mipomersen
is similar across all LDL phenotypes and genotypes including HeFH, non-familial
hypercholesterolemia and HoFH. Mipomersen was studied in addition to existing lipid-lowering
statin therapy.
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An adverse effect of APOB inhibitors is the accumulation of hepatic fat which can lead to
hepatitis and liver damage. In this study a significant limitation occurred when 30% of subjects
in both the placebo and mipomersen groups had unreadable magnetic resonance imaging (MRI)
scans. MRI scans were utilized to observe hepatic fat content to determine whether mipomersen
therapy should continue or cease. This technical and subject challenge had little effect on the
study since there were still an adequate number of readable MRI scans to make a conclusion with
and reach statistical significance (Stein et al., 2012).
In another study published by the European Heart Journal, mipomersen’s effects were
studied over two years to evaluate the effectiveness and safety of long-term dosing in individuals
with FH on maximally tolerated statin therapy. 142 patients were enrolled in the study (N=142)
with HeFH (n=103) and HoFH (n=38) respectively who had successfully and recently completed
a phase 3 mipomersen trial and did not have any adverse health conditions (clinically significant
liver laboratory results, injection site reactions, flu-like symptoms) and did not consume
excessive amounts of alcohol (Santos et al., 2013). Mipomersen was administered weekly at 200
mg subcutaneously and a 2 week screening period and 24 week follow up succeeded the test
where patients were assessed for drug efficacy and safety. Subject safety was monitored through
assessment and laboratory findings every 4-7 weeks and ECGs were conducted to examine QT
interval changes, a possible complication of mipomersen of which subjects were effected (n=2)
(Santos et al., 2013). Laboratory results were monitored for hepatic damage to drug therapy
(n=2), and other adverse effects (n=33). The most common adverse effect was noted to be
injection site reactions (n=138). Elevated liver enzymes (a reversible condition was found with
drug discontinuation) in the form of alanine aminotransferase were monitored and elevated in a
small number of subjects (n=18) (Santos et al., 2013).
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Effectiveness of mipomersen was noted by the 28-31% average reduction in APOB
concentrations (Santos et al., 2013). Also noted was the small reduction in triglycerides and
slight increase in HDL (P<0.01). Mean reduction in APOB by week 104 was 31% (P<0.001).
Reduction of triglycerides, non HDL cholesterol and LDL was noted throughout the study with a
17% decrease in LDL by week 104 (P<0.001) (Santos et al., 2013).
A serious limitation was the association of the authors to outside interests including
pharmaceutical companies and research firms exposes a conflict of interest for this study. The
authors either worked for or presented for pharmaceutical product developers. Another limitation
was the source of funding by Genzyme, a subsidiary of the Sanofi Corporation who paid for the
research and open publication of this study (Santos et al., 2013).
MTP Inhibitors
The MTP inhibitor’s mechanism lies in its ability to inactivate MTP, a precursor in the
construction of LDL and chylomicrons, both of which are lipoproteins. MTP inhibitors lower the
amount of apoliprotein B containing lipoproteins which in turn lowers non-HDL cholesterol
(Hewing et al., 2013). This study used rodents (mice) as subjects (N=24), to determine the
effectiveness of MTP inhibitors in regressing atherosclerotic lesions. The researchers
administered MTP inhibitors to the mice through dietary means in mice chow. MTP inhibitors
greatly reduced circulating LDL. By the end of one week serum LDL levels were reduced by
84% and by two weeks the level was reduced to by 94%. Atherosclerotic lesion size also were
decreased, became less fatty and became more collagenous which is a sign of plaque
stabilization in humans. Plaque size when comparing the MTP group against the control group
there was a 39.4% decrease in size (p<0.001) (Hewing et al., 2013). The only significant
limitation is this study was conducted on mice and not in humans: therefore findings may not be
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similar in human subjects. Along with a small sample (N=24) using mice is not clinically
significant for humans.
Another study by researchers in the UK observed correlations between MTP inhibitor use
and reduction of serum LDL (Kolovou, Vasiliadis, Gontoras, Kolovou, & Hatzigeorgiou, 2015).
The case-study included two subjects (N=2) and found the results cannot be either statistically
significant or clinically significant but the findings may be useful in developing future studies
focusing on FH. Both subjects were homozygous for FH, had severely elevated LDL levels (both
>300 mg/dL) and were required to undergo LDL-apherisis (a dialysis-like procedure that
removes LDL from the blood). Researchers found that serum LDL cholesterol could be reduced
by 40% when MTP inhibitors are combined with statin. LDL-apherisis was also impacted with
frequency dramatically reduced. In one subject undergoing apheresis every other week, MTP
inhibitors reduced need for the procedure to once every 10 to 12 weeks after 40 weeks of MTP
inhibitor use. Another subject had reduced apheresis to once every 16-24 weeks (Kolovou,
Vasiliadis, Gontoras, Kolovou, & Hatzigeorgiou, 2015).
Another MTP inhibitor lomitapide (Juxtapid) developed by pharmaceutical company
Aegerion in conjunction with the University Of Pennsylvania School Of Medicine is reported to
hold promise in HoFH individuals who have not responded to statins. In a phase 2 clincial trial,
researchers investigated lomitapide and atorvastatin (statin drug) combination therapy and how it
would compare to atorvastatin alone, the study (N=50) was conducted over 8 weeks. Researchers
found that in combination, lomitapide and atorvastatin significantly lowered serum LDL levels
than atorvastatin alone. The findings indicated Juxtapid reduces mean LDL levels 66% from
baseline compared to placebo when in combination with atorvastatin; lomitipide alone decreases
LDL by 35% from baseline (Aegerion Pharmaceuticals, 2011).
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Discussion
The serum LDL lowering effect of new classifications of Pharmacogenomic drugs is
evident with treatment of FH. More specifically, PCSK9 inhibitors, ApoB inhibitors and MTP
inhibitors all were found to have better outcomes for individuals with FH either as an adjunct or
replacement for traditional statin therapy. The variability of statins and the genetic factors that
predispose an individual to statin intolerance resulted in a gap for successfully treating
individuals with FH. Pharmacogenomics in some cases can be used as an adjunct to statin drugs
to achieve lower target LDL levels in FH individuals who are on maximum tolerated statin
therapy, or who do not tolerate statins. Pharmacogenomic therapies also have potential for
tailoring treatments for individuals with non-familial dyslipidemias as the aforementioned
pharmacotherapies have a substantial effect on serum LDL levels, ApoB, triglycerides and
chylomicrons and, in some cases, weight reduction.
Based on this review of only eight studies, the evidence suggests that genomic research
advances with genetically based pharmacotherapies can lower serum LDL levels in individuals
with a diagnosis of FH. However, additional studies are needed with larger sample sizes and
more diverse subjects. More information is being discovered about genetic traits and FH and the
role of precision medicine may have in managing symptoms and disease processes in individuals
with this genetic trait. As the HGP continues to uncover genetic markers for other disease, more
diagnostic and treatment options may become a reality for these conditions. While much remains
unknown, the research evidence in this review suggests that the new pharmacogenomic medicine
are effective in regulating the disease process of FH and hypercholesterolemia; thus, reducing
long term health risks and other associated comorbidities specifically, PCSK9 Inhibitors, ApoB
inhibitors and MTP inhibitors.
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Implications for Nursing
The next section highlights implications for nursing in respect to education, practice,
policy and research followed by limitations of this integrated review of the literature focusing on
the management of FH using pharmacogenomics.
Education
Given the mandate of the American Nurses Association and other professional nursing
specialty organizations (Cheek, Bashore, & Brazeau, 2015; Greco, Tinley, & Seibert, 2011;
Howington, Riddlesperger, Cheek, 2011), there is a need for nurse educators to integrate
genomics into content curricula. This nursing mandate, coupled with President Obama’s
Initiative on Precision Medicine reinforces an urgent need for a more robust understanding of
human genomes, pharmacogenomics and precision medicine (Williams et al., 2016). More
specifically, students must be informed about concepts related to human genetic traits in disease
formation which is vital in developing, treating and evaluating nursing care plans in particular
individuals who are at risk for or have been diagnosed with FH. As genetically based therapies
become more specific to the genome of an individual it is ever more important that nurses
understand precision therapie’s physiological processes (Cheek, Bashore, & Brazeau, 2015).
Informed health professionals, specifically nurses, can be more effective at patient education and
informing about genetic treatment principles. Not only is genetic related content important for
students in pre-licensure nursing education programs, but continue education offerings must be
mandatory for nurses who have been in the workforce for an extended period of time (Williams
et al., 2016).
Electronic resources are a source of current information that can augment nurses’
knowledge on genomics. For instance, the National Institute of Health Pharmacogenomics
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Research Network’s Clinical Pharmacogenetics Implementation Consortium (CPIC) (Caudle et
al., 2014) provides information on current research relating to genetics and precision medication.
This consortium, on a regular bases, releases peer-reviewed guidelines involving genetics and
pharmacogenomics data is useful to improve treatment outcomes (Cheek, Bashore, & Brazeau,
2015). The National Institute of Health’s Pharmacogenomics and Pharmacogenetics Knowledge
Base (PharmGKB) (Thorn, Klein, & Altman, 2013), is another site that provides current
evidence on pharmacogenomics that nurses in advanced practice, research and education can
readily access (Cheek, Bashore, & Brazeau, 2015).
Practice
Clinicians must understand genetics concepts as these relate to disease processes and
precision medicine for nursing assessments, care planning and outcomes evaluation. Core
competencies related to genetics and pharmacogenomics have been identified and are important
to enhance clinical reasoning and decision making (Williams et al., 2016). In the roles of
advocate, educator and counselor, nurses are expected to inform, assess, monitor and obtain
signed consent from individuals who are considering genomic screening and pharmacogenomic
treatment options. Nurses often educate individuals and family members about genetic tests;
sometimes interpret results along with the physiology of genome traits and mutations that can
lead to disease processes. The influence of genetic traits and the associated pharmacodynamics
and pharmacokinetics that inform about drug transport and metabolization are even more
important for advanced practice nurses to understand who are involved in prescribing and
titrating medications that are genome dependent (Cheek, Bashore, & Brazeau, 2015). Another
responsibility of nurse clinicians is administering and monitoring responses to pharmacogenomic
interventions (Cheek, Bashore, & Brazeau, 2015). In the case of an individual diagnosed with
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FH, the nurse would monitor serum LDL levels and interpret pertinent laboratory values as well
as monitor for side effects of the drug such as liver impairment.
Policy
Stated objectives of the Whitehouse Initiative on Precision Medicine include accelerating
biomedical research, providing health professionals with tools to treat genetic disease and
incorporating researcher and evidence based medical interventions (Williams et al., 2016). This
initiative at a societal level reinforces an urgent need for research on pharmacogenomics and
appropriately treating genetic induced conditions. In turn, the evidence should be disseminated
for use by clinicians to develop and implement precision interventions to treat and manage a
particular genetic based condition such as FH (Cheek, Bashore, & Brazeau, 2015). Nurses are in
a position to influence policy at national, state and local levels first by being informed; then,
contacting and informing policy makers about genetic related initiatives. Another policy
implication relates to reimbursement levels by third party payers for genetic screening and
precision medicine. While pharmacogenomics may initially be deemed to be more costly by 3rd
party payers, long term outcomes may be far more cost effective when applying
pharmacogenomics and precision medicine. As advocates, nurses must have a greater presence
on local, state and national advisory boards and other regulatory agencies in order to present the
nursing perspective as well as advocating for consumers, specifically, in the area of genomics
and FH.
Research
Based on a review of only eight articles for this thesis reinforces that limited research that
has been published in the area of FH and precision medicine to treat this genetically based
condition. There are multiple gaps in the literature. Studies are needed focusing on nursing
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topics, such as effective counseling approaches with individuals who are considering genetic
screening. Evidence is needed on appropriate educational strategies focusing on
pharmacogenomic interventions, managing associated side effects and supporting individuals
that are recipients of precision medicine. Additional research is needed that isolates FH
phenotypes and measuring short and long term drug efficacy with theses genetic traits; as well as
developing primary, secondary and tertiary prevention strategies. Since genomics and
pharmacogenomics are a new medical frontier, studies are needed that focus on demographic
diversity including gender, ethnic, racial and age factors to establish both statistical and clinical
significance.

Limitations
Several limitations are noted with this integrative review of the literature focusing on
pharmacogenomics in FH. Associated with the inclusion criteria limiting publication time frame
of five years 5 (2010-2015) that were written in the English language only eight articles were
reviewed; seven of which had a very small sample size; and, one of which used rodents as
subjects. The studies that were reviewed focused on select drugs and their effectiveness in
treating individuals with persistent hypercholesterolemia, with minimal information on the drug
effects on subgroups and side effects. There also was evidence of conflict of interests among the
researchers and their financial sponsor (pharmaceutical companies) for the studies.

Summary
The Human Genome Project has had far reaching applications for genomic technologies
and pharmacogenomic interventions that are tailored to human conditions that are associated
with genomic traits. Based on the integrative research literature review focusing on familial
hypercholesterolemia, there is a paucity of articles on the topic. The research predominately is on
19

emerging pharmacogenomic drugs and their effects on managing FH. This synthesis of eight
research articles by this researcher summarizes that little is known on the topic along with
extensive gaps in the evidence. Finally, implications for nursing education, practice, policy and
research along with limitations are noted.
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APPENDIX A

Figure 1: Selection Method of Literature
Initial search terms “Pharmacogenomics” OR “Pharmacogenetics,”
“genetics,” “genetic screening” and “nursing” using databases CINAHL,
MEDLINE, PubMed and Cochrane.
(n=18,312)

Revised search shifted to include the terms “familial
hypercholesterolemia” and drug class names
“PCSK9 inhibitors”, “APOB Inhibitors” and “MTP
inhibitors”

Other scholarly relevant and pertinent sources from
webpages that added to background
(n=4)

Inclusion criteria expanded to include dates 2010 to
2015

Narrowed Search to include “PCSK9”
(n=301)

(n=131)
Studies included that met inclusion criteria
(n=3)

Narrowed search to include the term “APOB
Inhibitors”

Narrowed search to include “MTP Inhibitors”

(n=27)

(n=31)
Studies Included that met inclusion criteria
Studies included that met inclusion criteria

(n=2)

(n=3)

Studies including familial
hypercholesterolemia (FH) were given
more consideration than those not
including FH. Given the paucity of
research studies looking at multiple
forms of hypercholesterolemia were
included.

Nine articles were included
to give further relevance
and background to this
review.
(n=9)

(n=8)

Limiters: English-language, peer reviewed, published between 2010-2015, included HMG-CoA
reductase inhibitors (statins) as a comparison drug.
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APPENDIX B

Table 3: Research Literature Reviewed

Author
(last/First name)

Date
of
study
2011

Study design Sample
size
Randomized
Controlled
Trial

N=50

Stein, E. A.,
Dufour, R., Gagne,
C., Gaudet, D.,
East, C., Donovan,
J. M., . . .
Mcgowan, M.

2012

Randomized
Controlled
Trial

N=124

Hewing, B.,
Parathath, S., Mai,
C. K., Fiel, M. I.,
Guo, L., & Fisher,
E. A.
Santos, R. D.,
Duell, P. B., East,
C., Guyton, J. R.,
Moriarty, P. M.,
Chin, W., &

2013

Animal
N=24
experimental

Laboratory/
MTP inhibitors reduce
Physiological LDL & size of
atherosclerotic lesions

Study conducted on mice instead
of humans.

2013

Randomized
Controlled
Trial

Laboratory

Authors had associations with
pharmaceutical companies.
Funding came from a
pharmaceutical company for
research and publishing.

Aegerion
Pharmaceuticals

N=142

Data
collection
method
Laboratory/
Imaging

Key Findings

Gaps/conflicting information

Lomitapide effective at
lowering LDL in
subjects with HoFH up
to 66%

Research supported by
pharmaceutical company. Could
be conflict of interest for
researchers at University of
Pennsylvania

Laboratory/
Imaging

ApoB inhibitors reduce
LDL in heterozygous
FH subjects by 28%
from baseline when
compared to a placebo
(p<0.001)

About 30% of MRIs not readable
to determine hepatic fat content;
medication side effect.
Significance of hepatic fat and
ALT level increases are uncertain.
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Safety and efficacy of
mipomersen in subjects
with FH. APOb
reduction was 31% at
104 weeks(P<0.001).

Mittleman, R. S.
Kereiakes, D. J.,
Robinson, J. G.,
Cannon, C. P.,
Lorenzato, C.,
Pordy, R.,
Chaudhari, U., &
Colhoun, H. M.
Kolovou, G.,
Vasiliadis, I.,
Gontoras, N.,
Kolovou, V., &
Hatzigeorgiou, G.
Raal, F. J.,
Honarpour, N.,
Blom, D. J.,
Hovingh, G. K., Xu,
F., Scott, R., . . .
Stein, E. A.
Raal, F. J., Stein, E.
A., Dufour, R.,
Turner, T., Civeira,
F., Burgess, L., . . .
Gaudet, D.

2015

Randomized
Controlled
Trial

N=316

Laboratory

2015

Case study

N=2

Laboratory

2015

Randomized
Controlled
Trial

N=50

Laboratory

2015

Randomized
Controlled
Trial

N=331

Laboratory
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HDL increased
(P<0.01).
PCSK9 inhibitors
reduce LDL by 48%
from baseline in
subjects at high CV
risk who were on
maximally tolerated
statins.
MTP inhibitors reduce
LDL by 40% in
homozygous FH
subjects on statin
therapy.
PCSK9 inhibitors
reduce LDL by 30.9%
compared to placebo
(p<0.0001) in
homozygous FH
subjects
PCSK9 inhibitors in
heterozygous subjects
reduce LDL by 60%
when compared with
placebo.

Relatively small for analysis of
subgroups.

Very small sample size that isn’t
statistically significant.

Short, 12 week study. Did not
control for some subgroups.

Analysis of response to treatment
based on genotype was not prespecified. Short duration of study,
only12 weeks.
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